David Collister1, Claudio Rigatto, Navdeep Tangri. 1. aSection of Nephrology, Department of Medicine, McMaster University, Hamilton, Ontario bChronic Disease Innovation Center, Seven Oaks General Hospital cSection of Nephrology, Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
Abstract
PURPOSE OF REVIEW: This review describes the current state of anemia management with erythropoietin (EPO)-stimulating agents and iron supplementation in both chronic kidney disease and dialysis patients, with a focus on novel therapies. RECENT FINDINGS: We review the benefits and risks of EPO-stimulating agents, focusing on health-related quality of life and the uncertainties regarding optimal iron utilization in patients with kidney disease. We discuss novel therapies for iron supplementation including iron-based phosphate binders and dialysate iron delivery as well as alternatives to EPO-stimulating agents including hypoxia-inducible factor prolyl hydroxylase inhibitors. SUMMARY: Individualization of hemoglobin targets using EPO-stimulating agents and iron supplementation may be considered in younger, healthier patients with kidney disease to improve health-related quality of life. Optimal iron utilization in kidney disease patients is unclear, but novel iron base phosphate binders and dialysate iron delivery may play a role in intravenous iron avoidance and its potential complications. Phase 3 randomized controlled trials of hypoxia-inducible factor prolyl hydroxylase inhibitors are ongoing and are promising new alternatives to EPO-stimulating agents and their known adverse effects.
PURPOSE OF REVIEW: This review describes the current state of anemia management with erythropoietin (EPO)-stimulating agents and iron supplementation in both chronic kidney disease and dialysis patients, with a focus on novel therapies. RECENT FINDINGS: We review the benefits and risks of EPO-stimulating agents, focusing on health-related quality of life and the uncertainties regarding optimal iron utilization in patients with kidney disease. We discuss novel therapies for iron supplementation including iron-based phosphate binders and dialysate iron delivery as well as alternatives to EPO-stimulating agents including hypoxia-inducible factor prolyl hydroxylase inhibitors. SUMMARY: Individualization of hemoglobin targets using EPO-stimulating agents and iron supplementation may be considered in younger, healthier patients with kidney disease to improve health-related quality of life. Optimal iron utilization in kidney diseasepatients is unclear, but novel iron base phosphate binders and dialysate iron delivery may play a role in intravenous iron avoidance and its potential complications. Phase 3 randomized controlled trials of hypoxia-inducible factor prolyl hydroxylase inhibitors are ongoing and are promising new alternatives to EPO-stimulating agents and their known adverse effects.
Authors: Bernard Canaud; Stefano Stuard; Frank Laukhuf; Grace Yan; Maria Ines Gomez Canabal; Paik Seong Lim; Michael A Kraus Journal: Clin Kidney J Date: 2021-12-27
Authors: Angelo Karaboyas; Hal Morgenstern; Sandra Waechter; Nancy L Fleischer; Raymond Vanholder; Stefan H Jacobson; Manish M Sood; Douglas E Schaubel; Masaaki Inaba; Ronald L Pisoni; Bruce M Robinson Journal: Clin Kidney J Date: 2019-07-05
Authors: Victor da Silva; Hugo Corrêa; Rodrigo Neves; Lysleine Deus; Andrea Reis; Michel Souza; Cláudio Dos Santos; Danilo de Castro; Fernando Honorato; Herbert Simões; Milton Moraes; Brad Schoenfeld; Jonato Prestes; Thiago Rosa Journal: Front Physiol Date: 2021-03-10 Impact factor: 4.566